New pill targets Hard-to-Treat cancers with AKT1 mutation
NCT ID NCT07038369
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This early-stage study tests an experimental pill, ATV-1601, in people with advanced solid tumors (including certain breast, ovarian, and prostate cancers) that have a specific AKT1 gene mutation. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 134 adults whose cancer has worsened after standard treatments will take the drug daily, either alone or with another medication called fulvestrant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Leon Berard
Lyon, 69008, France
-
Florida Cancer Specialists & Research Institute - Lake Mary
Lake Mary, Florida, 32746, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
START Madrid - CIOCC
Madrid, 28050, Spain
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.